Impaired renal function and bleeding in elderly treated with dabigatran

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 6, 2014, Pages 618-620

  Berthelot, Emmanuelle ^a   Lavenu Bombled, Cecile ^a   Orostegui Giron, Lupe ^a   Desconclois, Céline ^a   Assayag, Patrick ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

bleeding; dabigatran; elderly; renal failure

Indexed keywords

ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN;

AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLEEDING; BLOOD; CASE REPORT; CHEMICALLY INDUCED; DOSE CALCULATION; DRUG EFFECTS; FEMALE; HUMAN; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MALE; METABOLISM; PATHOLOGY; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG DOSAGE CALCULATIONS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; RENAL INSUFFICIENCY; STROKE;

EID: 84905825499     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000077     Document Type: Article

References (12)

1. Boehringer Ingelheim. Advisory committee briefing document. August 2012. (http://www.ema.europa.eu/.) www.ema.europa.eu/../en-GB/document-library/EPAR- Product-Information/human/000829/WC500041059.pdf [Accessed 17 December 2013]
2. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study. Circulation 2013; 128:237-243.
3. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation 2012; 126:2381-2391.
4. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272-1274.
5. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61:2264-2273.
6. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366:864-866.
7. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128:2325-2332.
8. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
9. Maccallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, Ashman N. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: A crosssectional study. BMJ Open 2013; 3:e003343.
10. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23:138-143.
11. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013; 15:625-651.
12. Douxfils J, DognéJM,Mullier F, Chatelain B, Rönquist-Nii Y, Malmstr0̈m RE, Hjemdahl P. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110:543-549.